Consumer group petitions FDA to halt Xenical sales

Consumer group Public Citizen Monday petitioned the FDA to remove Roche’s prescription version of Xenical (orlistat) from the market because of concerns of a link between the drug and colon cancer. “This drug, which treats obesity, causes a significant increase in the incidence of aberrant cyrpt foci, which are widely believed to be a precursor of colon cancer,” the petition said. Xenical has been on the market in the US since 1999. GlaxoSmithKline has proposed selling an OTC version of Xenical. The FDA Friday deemed orlistat approvable as an OTC drug but that GlaxoSmithKline had to meet certain conditions before the drug could be approved.
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.